2017 Fiscal Year Final Research Report
Establishment of an innovative vaccine platform with self-adjuvant function
| Project/Area Number |
26460560
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | ワクチン / ウイルス様粒子 / ナノキャリア / アジュバント / ドラッグデリバリー / 細胞傷害性T細胞 / HLA class I |
|---|
| Outline of Final Research Achievements |
When mice were immunized with antigenic epitope-inserted virus like particles (VLP) prepared from SV40, epitope-specific cytotoxic T cells (CTL) can be induced efficiently without adding an artificial adjuvant. Therefore, the self-adjuvant activity that activates innate immunity is considered to exist in VLP itself. In this study, I attempted to elucidate the mechanism of this self-adjuvant function using various approaches. Then, we identified molecules that showed a change in expression level by stimulation of VLP. VLP was also effective for mucosal immunity. Furthermore, it was shown that CTL can be efficiently induced by various CTL epitopes. These data indicate that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
|
| Free Research Field |
免疫学
|
